CANDICE MAROIS: Open Payments
NPI 1568941714 · PORT ORANGE, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$750 in 40 payments from 13 companies in 2025. Trend: 2023 $912 · 2024 $907 · 2025 $750
Food & beverage: $750
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 11 | $200 |
| Lilly USA, LLC | 4 | $69 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $69 |
| ALK-Abello, Inc | 3 | $65 |
| Novo Nordisk Inc | 3 | $62 |
| PFIZER INC. | 3 | $58 |
| Vanda Pharmaceuticals Inc. | 3 | $54 |
| AstraZeneca Pharmaceuticals LP | 2 | $39 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $33 |
| Amgen Inc. | 2 | $32 |
Products named: VRAYLAR, MOUNJARO, CAPLYTA, FANAPT, QULIPTA, AIRSUPRA, XIFAXAN, REPATHA.
Industry payments across FL — which companies pay providers there.
